china Archives - Journal for Clinical Studies

Regional News

China’s new NRDL; Biocon-Viatris biosimilar merger?; Avistone’s $200M series A

China unveiled new inclusions in its national reimbursement drug list, featuring novel therapies from Biogen, Pfizer, Eli Lilly and more. Partners Biocon and Viatris ...

13 December 2021 Regional News antibody drugs | ASLAN Pharmaceuticals

Continue Reading →

Regional News

GlaxoSmithKline vet departs for Vifor, the rumored target of a $7.1B CSL buyout

With a recent pruritus approval in the books and several more potential launches coming in the next year and a half, Switzerland’s Vifor Pharma is tapping longtime Gl...

13 December 2021 Regional News chief commercial officer | china

Continue Reading →

Regional News

Novo Nordisk, Sanofi and Eli Lilly cut insulin prices and lose share in China’s latest cost squeeze

On the centennial of the discovery of insulin, China decided a round of price cuts on the diabetes therapy is due. As a result, foreign companies Novo Nordisk, Sanofi...

1 December 2021 Regional News china | drug prices

Continue Reading →

Asia Pacific

CStone’s PD-1 inhibitor CS1003 gets clinical trial approval in China

CStone will initiate a multi-center Phase I clinical trial to assess the safety, tolerability and preliminary anti-tumor activity of CS1003 in Chinese patients with a...

18 July 2018 Asia Pacific | Europe approval | china

Continue Reading →

Rare Disease Ebook

Vaccine – Shorten Start-Up Timelines in Vaccine Trials

Current Edition

China’s new NRDL; Biocon-Viatris biosimilar merger?; Avistone’s $200M series A

GlaxoSmithKline vet departs for Vifor, the rumored target of a $7.1B CSL buyout

Novo Nordisk, Sanofi and Eli Lilly cut insulin prices and lose share in China’s latest cost squeeze

CStone’s PD-1 inhibitor CS1003 gets clinical trial approval in China

Journal for Clinical Studies